954258-03-8

Basic information

• Product Name: 5-BROMO-7-FLUORO-2,3-DIHYDRO-1H-INDOLE
• Synonyms: 5-BROMO-7-FLUORO-2,3-DIHYDRO-1H-INDOLE
• CAS NO: 954258-03-8
• Molecular Formula: C8H7BrFN
• Molecular Weight: 216.0502832
• Mol File: 954258-03-8.mol

Chemical Properties

• Boiling Point: 267.1±40.0 °C(Predicted)
• Appearance: /
• Density: 1.600±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 3.03±0.20(Predicted)
• CAS DataBase Reference: 5-BROMO-7-FLUORO-2,3-DIHYDRO-1H-INDOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-7-FLUORO-2,3-DIHYDRO-1H-INDOLE(954258-03-8)
• EPA Substance Registry System: 5-BROMO-7-FLUORO-2,3-DIHYDRO-1H-INDOLE(954258-03-8)

Safety Data

• Hazardous Substances Data: 954258-03-8(Hazardous Substances Data)

Upstream product

• 387-44-0 7-fluoro-1H-indole 
• 769966-04-3 2,3-dihydro-7-fluoro-1H-indole 

Relevant articles and documents

COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF

The invention relates to a compound of formula (I): wherein variables are as defined in the specification. The compound is an inhibitor of an ERK kinase, e.g. ERK1 and/or ERK2 kinase. The invention also relates to the use of the compound and a method for preparing the compound, and a pharmaceutical composition containing the compound.

4,5,6,7-TETRAHYDRO-1 H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS

The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

SULFONYLATED HETEROCYCLES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR

Compounds of the following structure are provided, wherein n, R1-R3 and R6-R9 are defined below, as are methods of preparing and using these compounds for contraception; treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, and hormone-dependent carcinomas; providing hormone replacement therapy; stimulating food intake; synchronizing estrus; and treating cycle-related symptoms.